IPO Profiles, April 2008

ArcSight Inc.

• Cupertino, Calif.
• 408-864-2600
• www.arcsight.com

Exchange and Ticker: Nasdaq: ARST

Filing Range: 6.00M shares @ $9.00 to $9.00

Offering Price: $9.00

Close on First Day: $8.78

Offering Size: $61.80M

Shares Outstanding: 30,941,015

Underwriters: Morgan Stanley

Co-managers: Wachovia Securities Inc./ RBC Capital Markets

Company Counsel: Fenwick & West LLP

Manager Counsel: Davis Polk & Wardwell

Auditor: Ernst & Young LLP

Market Capitalization on 2/29/08: $249.08M

Close price at current month end: $8.05

COMPANY DESCRIPTION

Provides enterprise security management solutions for internal and external threat management and compliance reporting. The company’s solutions integrate the management of heterogeneous security devices deployed across a network. By delivering real-time monitoring, correlation, investigation, resolution and reporting within a single solution, ArcSight enables the infrastructure that enables security organizations to manage information risk. Competitors include Check Point Software, Computer Associates, Internet Security Systems, RSA Security, Secure Computing, Symantec, Intellitactics and NetForensics.

VENTURE BACKERS

In-Q-Tel, Institutional Venture Partners, Integral Capital Partners, Kleiner Perkins Caufield & Byers, New Enterprise Associates, Samsung Venture Investment Corp.

Source: Thomson Financial

Bioheart Inc.

• Sunrise, Fla.
• 954-835-1500
• www.bioheartinc.com

Exchange and Ticker: Nasdq: BHRT

Filing Range: 3.58M shares @ $14.00 to $16.00

Offering Price: $5.25

Close on First Day: $5.00

Offering Size: $5.80M

Shares Outstanding: 14,447,138

Underwriters: Dawson James Securities

Co-managers: n/a

Company Counsel: Hunton & Williams

Manager Counsel: Dechert

Auditor: Grant Thornton LLP

Market Capitalization on 2/29/08: $65.45M

Close price at current month end: $4.53

COMPANY DESCRIPTION

Develops cellular-based heart muscle regeneration therapies. The company is focused on the discovery, development and commercialization of cellular-based therapy products for the treatment of cardiovascular diseases, including myocardial infarction, congestive heart failure and angina pectoris. Bioheart’s product candidate is MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from the patient’s body, for the purpose of improving cardiac function in chronic heart failure patients. Competitors include Medtronic Inc., Acorn Cardiovascular Inc., St. Jude Medical Inc., Guidant Corp., Pfizers Norvasc, Baxter International Inc. and Viacell Inc.

VENTURE BACKERS

Advent-Morro Equity Partners, Ascent/Meredith Asset Management, Guidant Corp. and Tyco Capital.

Source: Thomson Financial

MAKO Surgical Corp.

• Plantation, Fla.
• 954-927-2044
• www.makosurgical.com

Exchange and Ticker: Nasdaq: MAKO

Filing Range: 5.10M shares @ $14.00 to $16.00

Offering Price: $10.00

Close on First Day: $9.72

Offering Size: $51.00M

Shares Outstanding: 18,438,284 M

Underwriters: JP Morgan/ Morgan Stanley

Co-managers: Cowen/ Wachovia Securities Inc./ National Securities Corp.

Company Counsel: Hogan & Hartson

Manager Counsel: Latham & Watkins

Auditor: Ernst & Young LLP

Market Capitalization on 2/29/08: $193.97M

Close price at current month end: $10.52

COMPANY DESCRIPTION

Develops technologies and procedures for minimally invasive knee surgery. The company’s technology enables a surgeon to digitally sculpt and preserve bone tissue through small portals in a reproducible and simple manner. MAKO’s solution, called Makoplasty, targets early stage knee therapies. Competitors include Zimmer Holdings Inc., DePuy Orthopedics Inc., Stryker Corp., Biomet Inc. and Smith & Nephew Inc.

VENTURE BACKERS

Aperture Venture Partners, Exxel Group S.A., Ivy Capital Partners, Lumira Capital Corp., Sycamore Ventures, Tudor Ventures.

Source: Thomson Financial